Curanex Pharmaceuticals Inc Common Stock (CURX) vs Femasys Inc. (FEMY)
A side-by-side comparison of Curanex Pharmaceuticals Inc Common Stock and Femasys Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CURX
Curanex Pharmaceuticals Inc Common Stock
$4.96HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
FEMY
Femasys Inc.
$2.02HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CURX vs FEMY
growth of $100 · dividends reinvested · last 1yCURX -93.8% (-93.8%/yr)FEMY -80.4% (-80.4%/yr)FEMY compounded faster over this window
CURX FEMY
CURX vs FEMY: by the numbers
- •CURX is the larger company ($7M vs $6M market cap).
- •Both run net losses; CURX's is the smaller (0.00% vs -534.27% net margin).
Metrics side by side
Valuation
| Metric | CURX | FEMY |
|---|---|---|
| P/S ratio | N/A | 2.65 |
| P/B ratio | 1.47 | 1.51 |
Profitability
| Metric | CURX | FEMY |
|---|---|---|
| Gross margin | 0.00% | 61.96% |
| Operating margin | 0.00% | -763.90% |
| Net margin | 0.00% | -534.27% |
| ROE | -218.65% | -304.78% |
| ROIC | -208.39% | -209.05% |
Growth (annualized)
| Metric | CURX | FEMY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.97% |
| Total return CAGR (5Y) | N/A | -57.27% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.